After more than six years of high-stakes litigation in multiple courts and regulatory fights at the Food and Drug Administration (FDA), generic versions of Novartis Pharmaceuticals Corp.

MSN Laboratories Pvt. Ltd. can’t reopen disputes resolved in earlier litigation over the scope, validity, and infringement of ...

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported fourth-quarter adjusted earnings per share of $1.98, beating the street view of ...

The Third Circuit and Federal Circuit this week turned back Novartis’s requests for injunctions to block a version of its heart failure medication Entresto from generic maker MSN ...

FRANKFURT (Reuters) -Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter of the year, dragging the Swiss company's shares lower, as its top-selling drug comes ...

Earlier this month, the FDA approved an exciting new drug called Entresto, which is used to treat patients with congestive heart failure (CHF). CHF is a disease state in which the heart muscle becomes ...

CEO Narasimhan says no tariff impact on guidance Top-selling heart drug Entresto sees growth stall Older drugs hit by 'generic erosion' in US market Newer drugs help offset some of the slowdown ...